# (19) World Intellectual Property Organization

International Bureau



## (43) International Publication Date 25 August 2005 (25.08.2005)

PCT

# (10) International Publication Number WO 2005/076783 A2

(51) International Patent Classification: Not classified

(21) International Application Number:

PCT/US2004/040383

(22) International Filing Date: 3 December 2004 (03.12.2004)

(25) Filing Language:

English

(26) Publication Language:

**English** 

(30) Priority Data: 60/526,772

4 December 2003 (04.12.2003) US

- (71) Applicant (for all designated States except US): 3M INNOVATIVE PROPERTIES COMPANY [US/US]; 3M Center, Post Office Box 33427, Saint Paul, Minnesota 55133-3427 (US).

MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

### Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, DI, LL, IN, SI, JP, KE, KG, KF, RR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MX, MZ, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, MZ, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NA, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NX, NI, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NX, NI, NI, NO, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NX, NI, NI, NI, ND, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NX, NI, NI, ND, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NX, NI, NI, ND, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NX, NI, NI, ND, NZ, OM, MD, MG, MK, MN, MW, MX, MX, NX, NI, NI, ND, NZ, OM, MD, MG, MK, MW, MW, MX, MX, NX, NI, ND, NZ, OM, MD, MG, MK, MW, MW, MX, MX, NX, NI, NI, ND, NZ, OM, MD, MG, MK, MW, MW, MX, MX, NX, NI, ND, NZ, OM, MD, MG, MK, MW, MX, MX, NX, NI, ND, NZ, OM, MD, MG, MK, MW, MW, MX, MX, NX, NI, ND, NZ, OM, MD, MG, MK, MW, MX, MX, NX, NX, NI, ND, NZ, OM, MD, MG, MK, MW, MX, MX, NX, NI, ND, NZ, OM, MD, MM, MX, MX, NY, NY, ND, NY CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,

maceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

